THE NON-INVASIVE MARKERS FOR THE DIAGNOSIS AND FOLLOW-UP OF INFLAMMATORY BOWEL DISEASES: SERUM ADAMTS-7 AND ADAMTS-12
Öz
Aim: In this study, we aimed to evaluate the usability of ADAMTS-7 and ADAMTS-12 which are associated with inflammation as non-invasive markers for the diagnosis and follow-up of IBD
Materials and Methods: A total of 200 patients with IBD were included in this study. 96 of patients had ulcerative colitis (UC) (48 active, 48 in remission), 104 had Crohn’s disease (CD) (53 active, 51 in remission), and 40 healthy controls were included. Disease activity scores in UC and CD, laboratory parameters, and ADAMTS-7 and ADAMTS-12 values in all groups were studied and compared using statistical methods.
Results: ADAMTS-7 and ADAMTS-12 levels were significantly lower in the UC group than in the healthy control group (p=0.035 and p < 0.001; respectively). ADAMTS-7 and ADAMTS-12 levels were also significantly lower in the CD group than in the healthy control group (p=0.026 and p < 0.001; respectively). In patients with CD, a significant difference was identified between the levels of ADAMTS-7 and ADAMTS-12 in patients with perianal disease compared to those without perianal disease (p=0.026 and p < 0.001, respectively). There was no significant difference in ADAMTS-7 and ADAMTS-12 levels between UC and CD patients(p>0.05). UC groups age was between 18-64 years with mean 47.26 and CD group’s age were between 18-65 years with mean 41.52 .
Conclusions: The study shows that serum ADAMTS-7 and ADAMTS-12 levels can be valuable as non-invasive tests for the diagnosis of UC and CD and for predicting the presence of perianal disease in CD.
Anahtar Kelimeler
Kaynakça
- 1. Koçhan K, Erdem E, Babacan G, Paker N, Gökden Y, Saltürk AD ve ark. Inflamatuvar barsak hastalıklarının aktivite tayininde endoskopik aktivite indeksleri ile laboratuvar parametreleri arasındaki ilişki. Akademik Gastroenteroloji Dergisi. AGD. 2014;13(3):101-6.
- 2. Aebisher D, Bartusik-Aebisher D, Przygórzewska A, Oleś P, Woźnicki P, Kawczyk-Krupka A. Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies. Int J Mol Sci. 2024;26(1):121.
- 3. Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Chronisch entzündliche darmerkrankungen. Dtsch Arztebl Int. 2016;113(5):72-82.
- 4. Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106(8):123-33
- 5. Stange E, Travis S, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. {paVon} Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Rinisch W, European Crohn’s and Colitis Organisation European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut.2016;55(1):1-15.
- 6. Vos MD, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19(10):2111-7.
- 7. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26(10):1493-9.
- 8. Clark C, Turner J. Diagnostic modalities for inflammatory bowel disease: serologic markers and endoscopy. Surg Clin North Am. 2015;95(6):1123-41.
- 9. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162-9.
- 10. Kozioł K, Owczarek D, Cibor D, Zwolińska-Wcisło M. Serum level of lactadherin (MFGE8) in inflamatory bowel disease. Folia Medica Cracov. 2023;63(3):15-29.